在第三季度，天士力公告其创新药研发取得多项成果。公司重磅生物创新药普佑克此前刚获得国家药监 局批准新增适应症，用于急性缺血性脑卒中（AIS）的溶栓治疗；公司另有一款中药产品获批上市，一 款化药获准开展用于晚期实体瘤临床试验。 公司半年报显示，天士力目前在研管线中创新药达31项。其中，公司不仅在创新中药领域有近20款临床 中后期产品持续推进，而且在市场关注度高的生物创新领域已有布局，多款CGT、抗体药物等热门靶点 药品进入临床。 围绕心血管及代谢、神经/精神、消化三大疾病领域，公司重点布局先进治疗药品等技术壁垒高、临床 价值高的品种，避免了在"红海"领域的过度竞争。已获得人脐带间充质干细胞注射液、脂肪间充质基质 细胞注射液、双靶点 CAR-T 细胞注射液 3 项临床批件，其中脂肪间充质基质细胞注射液是全球首款基 于基质细胞原理获批美国IND的治疗产品。重点品种PD-L1/VEGF 双抗，能同时阻断 PD1/PD-L1 通路和 VEGF/VEGFR通路，增加肿瘤组织的淋巴细胞浸润，降低对 PD-1/PD-L1 抗体的耐药，协同发挥抑制肿 瘤生长的作用，增强抗肿瘤活性，其针对实体瘤适应症 IIa 期、结直肠癌适应症 ...

Investment Rating - The report maintains a "Buy" rating for the company [5][8] Core Views - The company's performance is in line with expectations, with a focus on innovation-driven growth [2][12] - The company achieved a revenue of 4.29 billion yuan in the first half of 2025, a year-on-year decrease of 1.9%, while the pharmaceutical industrial segment showed resilience with a revenue of 3.88 billion yuan, down 0.5% year-on-year [12] - The management efficiency is expected to improve following the completion of the acquisition by China Resources Sanjiu, which is anticipated to enhance long-term growth [12] - The company is accelerating its R&D pipeline with 83 projects in progress, focusing on innovative products in key therapeutic areas [12] Financial Summary - The company forecasts earnings per share (EPS) of 0.75, 0.89, and 0.95 yuan for 2025, 2026, and 2027 respectively [5] - Projected revenues for 2025, 2026, and 2027 are 9.069 billion, 9.723 billion, and 10.248 billion yuan, reflecting growth rates of 6.7%, 7.2%, and 5.4% respectively [7][14] - The net profit attributable to the parent company is expected to be 1.124 billion, 1.325 billion, and 1.423 billion yuan for 2025, 2026, and 2027, with year-on-year growth rates of 17.6%, 17.9%, and 7.4% respectively [7][14] - The company's gross margin is projected to remain stable around 66.5% to 66.7% over the next few years [7][14]

Investment Rating - The report maintains a "Buy" rating for the company [5][8] Core Views - The company's performance is in line with expectations, with a focus on innovation-driven growth [2][12] - The company achieved a revenue of 4.29 billion yuan in the first half of 2025, a year-on-year decrease of 1.9%, primarily due to adjustments in retail channels affecting the pharmaceutical commercial sector [12] - The pharmaceutical industrial sector showed resilience, with a revenue of 3.88 billion yuan, down 0.5% year-on-year [12] - The completion of the acquisition by China Resources Sanjiu is expected to enhance management efficiency and long-term growth potential [12] - The company is accelerating its R&D pipeline, focusing on innovative products, with 83 projects in development, including 31 innovative drugs [12] Financial Summary - The company forecasts earnings per share (EPS) of 0.75, 0.89, and 0.95 yuan for 2025, 2026, and 2027 respectively [5] - Projected revenues for 2025, 2026, and 2027 are 9.069 billion, 9.723 billion, and 10.248 billion yuan, reflecting growth rates of 6.7%, 7.2%, and 5.4% respectively [7] - The net profit attributable to the parent company is expected to be 1.124 billion, 1.325 billion, and 1.423 billion yuan for 2025, 2026, and 2027, with year-on-year growth rates of 17.6%, 17.9%, and 7.4% respectively [7] - The gross margin is projected to remain stable around 66.5% to 66.7% over the forecast period [7]

Core Viewpoint - The company reported a slight decline in revenue for H1 2025, but a significant increase in net profit, indicating a mixed financial performance amidst strategic adjustments and ongoing integration with China Resources [1][2]. Financial Performance - For H1 2025, the company achieved revenue of 4.288 billion yuan, a year-on-year decrease of 1.91% [1]. - The net profit attributable to shareholders was 775 million yuan, reflecting a year-on-year increase of 16.97% [1]. - The non-recurring net profit was 640 million yuan, down 12.87% year-on-year [1]. - In Q2 2025, revenue was 2.233 billion yuan, a decline of 3.86% year-on-year, while net profit rose by 25.41% to 460 million yuan [1]. Industry Performance - The pharmaceutical industry maintained stability, with the company's pharmaceutical manufacturing segment generating revenue of 3.879 billion yuan, remaining flat year-on-year [2]. - The pharmaceutical commercial segment saw a revenue decline of 14.88%, totaling 386 million yuan [2]. - The company adjusted its product classification, now categorizing products by treatment area rather than type, aligning with future strategic goals [2]. Strategic Integration - The integration with China Resources is progressing smoothly, expected to bring positive changes [3]. - Following the acquisition completion on March 27, 2025, the company is implementing a "100-day integration" plan focusing on operational management, strategic planning, and channel expansion [4]. - The collaboration with China Resources' health consumer goods business aims to enhance strategic partnerships with leading retail pharmacies [4]. R&D Pipeline - The company is increasing its R&D efforts, focusing on cardiovascular, neurological, and digestive health, with 83 projects in the pipeline, including 31 innovative drugs [5][6]. - Seven clinical research projects were initiated in H1 2025, with 29 projects currently in clinical trials, including 21 in phases II and III [6]. - The company is advancing modern traditional Chinese medicine and focusing on biopharmaceuticals, having received clinical approvals for several innovative products [6]. Profit Forecast - Revenue projections for 2025-2027 are 8.660 billion yuan, 9.324 billion yuan, and 10.081 billion yuan, respectively [7]. - Expected net profits for the same period are 1.196 billion yuan, 1.331 billion yuan, and 1.484 billion yuan, with corresponding diluted EPS of 0.80 yuan, 0.89 yuan, and 0.99 yuan [7].